Dyne Therapeutics launches with $50 million for oligonucleotide muscle delivery
Wednesday, April 3, 2019 - 05:40
in Biology & Nature
The startup, founded by Atlas Ventures, is developing antibody-oligonucleotide conjugates for genetic muscle diseases